Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
A.et al (2013)
aureus 12
Assessment of risk of bias Due to the great disparity in study designs (clinical and basic research) available for each candidate biomarkers of interest, we did not use ROC curve analysis as a selection criterion to address robustness, but instead included the presence of at least one study per biological compartment including at least 30 individuals per group as a mandatory criterion
.webp)
In 2019, a proof of concept, phase IIa open label study in Germany aimed to evaluate the safety and efficacy of melanotan I implants in patients with XP [12]
US$ 25.63
US$ 25.34
US$ 21.90
US$ 27.96
US$ 26.10
US$ 24.51
US$ 27.90
US$ 28.20
US$ 23.66
US$ 27.16
